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Abstract
Background: L-arginine infusion improves endothelial function in malaria but its safety profile has not been described in
detail. We assessed clinical symptoms, hemodynamic status and biochemical parameters before and after a single L-arginine
infusion in adults with moderately severe malaria.
Methodology and Findings: In an ascending dose study, adjunctive intravenous L-arginine hydrochloride was infused over
30 minutes in doses of 3 g, 6 g and 12 g to three separate groups of 10 adults hospitalized with moderately severe
Plasmodium falciparum malaria in addition to standard quinine therapy. Symptoms, vital signs and selected biochemical
measurements were assessed before, during, and for 24 hours after infusion. No new or worsening symptoms developed
apart from mild discomfort at the intravenous cannula site in two patients. There was a dose-response relationship between
increasing mg/kg dose and the maximum decrease in systolic (r= 0.463; Spearman’s, p = 0.02) and diastolic blood pressure
(r = 0.42; Pearson’s, p = 0.02), and with the maximum increment in blood potassium (r = 0.70, p,0.001) and maximum
decrement in bicarbonate concentrations (r = 0.53, p = 0.003) and pH (r = 0.48, p = 0.007). At the highest dose (12 g), changes
in blood pressure and electrolytes were not clinically significant, with a mean maximum decrease in mean arterial blood
pressure of 6 mmHg (range: 0–11; p,0.001), mean maximal increase in potassium of 0.5 mmol/L (range 0.2–0.7 mmol/L;
p,0.001), and mean maximal decrease in bicarbonate of 3 mEq/L (range 1–7; p,0.01) without a significant change in pH.
There was no significant dose-response relationship with blood phosphate, lactate, anion gap and glucose concentrations.
All patients had an uncomplicated clinical recovery.
Conclusions/Significance: Infusion of up to 12g of intravenous L-arginine hydrochloride over 30 minutes is well tolerated in
adults with moderately severe malaria, with no clinically important changes in hemodynamic or biochemical status. Trials of
adjunctive L-arginine can be extended to phase 2 studies in severe malaria.
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Introduction
Although treatment with the rapidly acting anti-parasitic drug,
artesunate has significantly improved survival in severe malaria,
the case-fatality rate remains high [1]. Adjunctive treatments that
target underlying pathophysiologic processes in severe malaria
may reduce mortality further but none have been shown to be
efficacious to date [2,3].
L-arginine is the substrate for synthesis of nitric oxide (NO) from
NO synthase, and has been proposed as a potential adjunctive
therapy in severe malaria [4,5]. The rationale for this is based on
previous findings in severe malaria of impaired NO production
[5,6], hypoargininemia [4], near-universal impairment of NO-
dependent endothelial function [5] and a close association between
the improvement in endothelial function and recovery of plasma
L-arginine concentrations after treatment of severe malaria [7].
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NO down-regulates endothelial inflammation [8] and reduces the
cytoadherence of parasitized erythrocytes in vitro [9]. Endothelial
dysfunction, a measure of both impaired endothelial cell NO
bioavailability and endothelial cell activation [10], may exacerbate
other underlying processes in severe malaria including cytoadher-
ence of parasitised red cells to activated endothelial cells,
microvascular obstruction and tissue hypoxia. In severe malaria,
impaired endothelial function is associated with markers of
impaired perfusion, endothelial activation, and with increased
parasite biomass [5]. We have recently demonstrated that L-
arginine infusion is able to improve NO bioavailability and
endothelial function in patients with moderately severe malaria
[5], suggesting the potential for a similar effect if used as adjunctive
therapy in severe malaria.
Intravenous L-arginine has been used for over 40 years in
routine clinical practice to assess the integrity and function of the
hypothalamic-pituitary axis [11], where it is generally well-
tolerated when infused in large doses (30g; ,0.5 g/kg) over
30 minutes. More recently it has also been evaluated as a
therapeutic agent to improve endothelial function in cardiovascu-
lar diseases. Studies in healthy volunteers [12] and patients with
cardiovascular disease [13,14] have shown L-arginine infusion to
be safe with minimal side effects. Adverse events reported with
intravenous L-arginine in these settings include modest dose-
dependent effects on blood pressure, potassium and phosphate
[15,16] and a potential for effects on acid base status [14] and
blood glucose [17,18] . However, data on the hemodynamic and
biochemical changes resulting from infusion of L-arginine in
patients with acute inflammatory states have not been well
documented.
As a prelude to assessing the safety and potential utility of
adjunctive L-arginine infusion in severe malaria, we undertook a
safety, pharmacokinetic and efficacy study in patients with
moderately severe falciparum malaria (MSM). The efficacy of L-
arginine in improving endothelial function and NO production in
these patients has been reported previously [5]. Here we describe
detailed data on the safety of L-arginine infusion in the same group
of patients, with a focus on the hemodynamic and biochemical
changes and other potential adverse effects previously reported or
hypothesized in other clinical settings [14]. In seeking to evaluate
clinical safety we specifically sought the maximum change in the
vital signs and biochemical markers at any time during and after
L-arginine infusion compared to baseline readings. While not
reflecting the mean changes across the infusion and post-infusion
periods, this approach identified the ‘‘worst-case scenario’’,
however transient, for each parameter.
Methods
The protocol for this trial is available as supporting information;
see Protocol S1.
Study Site and Study design
The study was conducted at Mitra Masyarakat Hospital
(RSMM) in Timika, Papua, Indonesia, a region with unstable
transmission of multidrug-resistant Plasmodium falciparum and P.
vivax [19]. The design was a single ascending dose study of the
safety, pharmacokinetics and preliminary efficacy of adjunctive L-
arginine infusion. Patients were sequentially enrolled after written
informed consent was obtained.
Participants
Patients comprised adults $18 years of age with moderately
severe falciparum malaria (MSM) defined as fever or history of
fever in the past 48 hours, with .1000 asexual P. falciparum
parasites/mL (a threshold for clinical falciparum malaria in Papua
[20]), with no other etiology identified, requiring inpatient
parenteral therapy because of inability to tolerate oral therapy.
Patients exhibiting WHO warning signs or criteria for severe
malaria were excluded [21]. Other exclusion criteria included:
pregnant or breastfeeding women, patients treated with anti-
malarials for .18 hours, mixed P. falciparum/P. vivax infections,
diabetes, known cardiac, renal or hepatic disease, concurrent
infection and a haemoglobin ,6 g/dl, systolic blood pressure
,100 mmHg, a baseline venous bicarbonate level ,20 mEq/L,
potassium $4.2 mmol/L, glucose ,4 mmol/L, or chloride
.106 mmol/L. Individuals were treated with intravenous quinine
in accordance with national guidelines and also received
doxycycline or clindamycin. Decisions regarding provision of
additional supportive care, including antibiotics and fluid
administration, were made by the treating clinician.
L-arginine Infusion
L-arginine hydrochloride (Pharmalab, Sydney, Australia) was
diluted in 100 ml normal saline (or sufficient to provide a
concentration #10% w/v) and administered intravenously by an
infusion pump over 30 minutes at doses of 3 g, 6 g and 12 g.
Intravenous quinine was continued during infusion of L-arginine,
through a separate cannula.
Clinical Observations
Upon enrolment and before infusion, patients had a standardized
clinical history and physical examination recorded. During infusion
patients were monitored with serial assessments of the following
symptoms (nausea, vomiting, fever, giddiness, numbness of hands or
feet, flushing of face, difficulty breathing, cough, pain at infusion
site, rash, WHO dangers signs [21] and vital signs (systolic and
diastolic blood pressure, pulse rate, respiratory rate, temperature) at
10 minute intervals. After infusion, vital signs and symptoms were
obtained at intervals of 15 minutes for the first hour, 30 minute for
the next 3 hours, 4 hourly until 24 hours, and 12 hourly until
discharge. In total, 21 observations were obtained, 4 before, 3
during and 14 after infusion. Before, during and up to four hours
after infusion, patients were also monitored for arrhythmias with a
continuous electrocardiogram attached to the limb leads. We used
an automated sphygmomanometer to measure blood pressure and a
digital thermometer for axillary temperature.
Biochemical Measurements
Venous blood samples were taken 30 minutes before and
immediately prior to the start of the infusion and again at the end
of the 30 minute infusion. Further samples were taken 5, 20, 45,
60, 90 minutes and 2, 4, 8, 24 hours after the end of the infusion.
In total, 12 venous blood samples were taken, 2 before infusion
and 10 after. Measurements for blood potassium, glucose,
bicarbonate, pH, chloride, anion gap and phosphate concentra-
tions were performed on all samples. These were chosen based on
previously reported or hypothesized effects of L-arginine on these
markers. Lactate concentrations were measured on the venous
sample obtained immediately prior to infusion and at 4 hours.
Plasma creatinine, creatine kinase, bilirubin and liver enzymes
(AST, ALT and alkaline phosphatase) were measured at baseline
and 24 hours after infusion.
Laboratory Methods
Electrolytes, glucose, acid-base parameters and were measured
using a bedside biochemical analyser (i-STAT Corp, Windsor, NJ,
Safety of Arginine in Malaria
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USA). Plasma phosphate, serum creatinine, bilirubin, liver
enzymes and creatine kinase were measured using colorimetric
and enzymatic methods (Cobas 800, Roche Diagnostics).
Statistical Methods
Mean values of the vital sign and biochemical parameters before
infusion were compared to mean values obtained immediately
after infusion using a paired t-test (for continuous variables with a
normal distribution or variables log transformed to a normal
distribution). If parameters were not normally distributed, values
before and after infusion were compared by the Wilcoxon Signed
Rank Test. Because analysis in this manner could mask transient
but potentially clinically significant changes in a minority of
subjects, we also analyzed the maximum change in the vital signs
and biochemical markers at any time during and after L-arginine
infusion compared to baseline readings. This gave a ‘‘worst-case
scenario’’, however transient, for each parameter. The mean of the
pre-infusion values in each patient was subtracted from the lowest
(SBP, DBP, glucose, bicarbonate, phosphate, pH) and highest
(pulse rate, respiratory rate, potassium, chloride and anion gap)
measurement during infusion or in the two hours following
infusion and expressed as mean maximum change. Relationships
between the maximum changes and the dose weight ratio
(expressed as mg/kg) were assessed by Pearson’s correlation
matrix (r), or Spearman’s rank correlation coefficient (r) if the
dependent variable was not normally distributed. A general linear
model was used to assess dose-response relationships. All analyses
were performed with Stata 9.2 software (Statacorp). A two sided
value of p,0.05 was considered significant.
Ethical approval was obtained from the respective committees
of the National Institute of Health Research and Development,
Jakarta, Indonesia and the Menzies School of Health Research,
Darwin, Australia and the trial was registered in clinicaltrials.gov
as NCT00147368. The funders had no role in the study design,
data collection, analysis, decision to publish or preparation of the
manuscript.
Results
Patients
A total of 30 patients received a single L-arginine infusion
intravenously, at doses of 3 g (n = 10), 6 g (n = 10) and 12 g
(n = 10). The corresponding mean mg/kg doses in each group
were 53 mg/kg (range: 45–63), 105 mg/kg (range: 87–140) and
205 mg/kg (range: 155–240), respectively. Table 1 shows
baseline patient characteristics. The mean time to enrolment
was 6 hours after starting intravenous quinine (range 2–12 hours).
Clinical adverse effects during L-arginine infusion
Two patients, one receiving 3 g and another 12 g developed
mild discomfort over the intravenous cannula site during infusion,
but no signs of phlebitis were evident and no extravasations
occurred. No other patients developed new symptoms. There was
also no worsening of existing symptoms either during or after
infusion of L-arginine; in particular, no new or worsening
complaints of headaches, vomiting, nausea, flushing, giddiness,
dyspnea, cough, diarrhea, lethargy and anorexia. No allergic
reactions were seen.
Effect of L-arginine on vital signs
There were no statistically or clinically significant effects on
pulse rate (data not shown) or respiratory rate (data not shown)
before and during or after infusion of any dose of L-arginine, with
continuous electrocardiography remaining normal throughout.
Although the mean systolic and diastolic blood pressure did not
change significantly following the 3 g and 6 g arginine infusion,
patients given 12 g had a transient mean decrease in systolic
(5 mmHg [95%CI 3 to 8 mmHg]; p= 0.01) and diastolic
(5 mmHg [95%CI 0.5 to 9 mmHg]; p = 0.03) blood pressures
measured immediately at the end of infusion which returned
towards baseline within 15 minutes (Figure 1B and 1D). The
maximum falls in blood pressure at any time during or in the two
hours after infusion were also assessed. The maximum decrease in
both the systolic (r=0.463; Spearman’s, p = 0.002; Figure 1A)
and diastolic blood pressure (r = 0.42; Pearson’s, p = 0.02;
Figure 1C) correlated with increasing mg per kg dose. Each
increment of dose was associated with an increase in the mean
maximum decrement in systolic blood pressure of 3 mmHg
(p= 0.004; 95%CI: 1–5 mmHg) but not in diastolic blood pressure
(p = 0.094). Patients who received 3, 6 and 12 g had mean
maximum decreases in mean arterial blood pressure of 1.2 mmHg
(range 0 to 8), 4 mmHg (range 1 to 10) and 6 mmHg (range: 0 to
11; p,0.001) respectively. In no patient did systolic blood pressure
fall to 90 mmHg or less. Table 2 shows the maximum changes in
the systolic and diastolic blood pressures up to 2 hours after the
start of infusion when compared to pre-infusion values in each
dosing group.
Effect of L-arginine on electrolytes, pH and glucose
The maximum increases in potassium, chloride and anion gap,
and the maximum decreases in bicarbonate, pH, glucose, and
phosphate were assessed following L-arginine infusion. Each dose
increase of 100 mg per kg of L-arginine was associated with a
mean maximum increment in blood potassium of 0.2 mmol/
L(95%CI: 0.1–0.3)[r = 0.7; Pearson’s, p,0.001; Figure 2A]. In
patients given 12 g there was a statistically significant mean
Table 1. Baseline characteristics of patients who received L-
arginine infusions
Number 30
Age; mean (range), y 28 (18–54)
Males, No. (%) 20 (67)
Weight; mean (range), kg 58 (42–70)
Ethnicity, No. (%) Papuan highlander 23 (77)
Systolic blood pressure; mean (range), mmHg 109 (90–138)
Mean arterial blood pressure; mean (range), mmHg 83 (66–116)
Percentage hypertensive on enrolment 0%
Pulse rate; mean (range), beats/minute 80 (54–116)
Respiratory rate; mean (range), breaths/minute 24 (18–32)
Temperature; mean (range), uC 37 (34.8–40.2)
Potassium; mean (range), meq/L 3.2 (2.6–3.8)
Bicarbonate; mean (range), meq/L 24.1 (20.1–29.6)
Chloride; mean (range), meq/L 102 (95–105)
Phosphate; mean (range), meq/L 1.1 (0.7–2.2)
Glucose; mean (range), mmol/L 7.6 (4.8–14.5)
Haemoglobin; mean (95% CI), g/L 123 (75–170)
Plasma L-arginine; mean (95%CI), mmol/L 37 (33–43)
Lactate concentration; mean (95%CI), mmol/L 1.5 (1.2–1.8)
Parasite density; geometric mean (range), ml21 17,221 (890–
281,864)
doi:10.1371/journal.pone.0002347.t001
Safety of Arginine in Malaria
PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2347
increase in potassium of 0.5 mmol/L (range 0.2 to 0.7 mmol/L;
p,0.001; Figure 2B), peaking at the completion of infusion. In
no patient did potassium concentrations rise above 4.6 mmol/L
(normal range: 3.3–5.0 mmol/L). For bicarbonate concentrations,
a maximum decrement in bicarbonate concentrations of 1.2 meq/
L (95%CI: 1.9–0.45)(r = 0.53; Pearson’s, p = 0.003; Figure 3A)
was noted with each increase of 100 mg/kg L-arginine; in those
receiving the 12 g dose, the mean decrease in bicarbonate was 3
mEq/L (range 1 to 7; p,0.01; Figure 3B). There was a also a
mean maximal decrease in pH of 0.02 (95%CI: 0.03–
0.005)(r = 0.48; Pearson’s, p = 0.007; Figure 4A) per 100 mg/kg
increase in L-arginine dose, but there was no significant change in
mean pH in the patients given 12 g (Figure 4B). No patient had a
bicarbonate concentration which dropped below 17 mEq/L
(normal range 20–30 mEq/L) or a pH that fell below 7.34. There
was a mean increment in chloride of 1.0 mmol/L(95%CI: 0.5–
1.6; r = 0.6; Pearson’s’ p,0.001) per 100 mg/kg increase in L-
arginine dose (Figure 5A). Following the 12 g dose, mean
chloride concentrations increased from 101 (95%CI: 99 to 102) to
103 (95%CI: 102 to 104) mmol/L (normal range 97–110 mmol/
L) (Figure 5B), with a mean maximal increase of 3 mmol/L
(range 1 to 5; p,0.001).
When categorized by dosage group (3g vs 6g vs 12g), there was a
linear-dose response, with each dose increment associated with an
increase in the mean maximum potassium increment (0.19 mmol/
L [95%CI: 0.12 to 0.25 mmol/L] p,0.001), the mean maximum
bicarbonate decrement (1.9 mEq/L [95%CI: 0.12 to 4.8 mEq/L];
p = 0.004) and the mean maximum pH decrement (0.017 [95%CI:
0.006 to 0.027]; p = 0.003) (Table 2).
There was no change in lactate concentrations following
infusions of any dose; and no dose-weight association (p = 0.7;
Figure 6A). There was no significant change in the anion gap
before and immediately after infusion at any dose, and no
association was seen between the dose-weight of L-arginine given
and the maximum change in anion gap (p= 0.9; Figure 6B).
There was no correlation between dose (either mg/kg or dosage
group) and the maximum change in phosphate (Figure 7A) or
glucose (Figure 8A). In addition, no significant changes were
found in mean phosphate (Figure 7B) or mean glucose
(Figure 8B) concentrations following the 12 g L-arginine
infusion. One patient who received 3 g of L-arginine had a
decrease in blood glucose from 6.7 mmol/L to 3.2 mmol/L but
did not reach the range considered hypoglycemic (,3 mmol/L).
This occurred 60 minutes after the completion of the L-arginine
Figure 1. Effects of L-arginine hydrochloride infusion on blood pressure. Figure 1A: Relationship between dose/weight (mg/kg) of infused
L-arginine and the maximal fall in systolic blood pressure at any time during or in the two hours following infusion (n = 30; r=20.463, p = 0.015).
Figure 1B: The systolic blood pressure profiles of patients before, during and up to 120 minutes after 30 minute administration of the highest dose
of L-arginine (12 g; n = 10). Shaded area indicates time of L-arginine infusion. Dots and bars indicate mean6SEM. Figure 1C: Relationship between
dose/weight (mg/kg) of infused L-arginine and the maximal fall in diastolic blood pressure at any time during or in the two hours following infusion
(n = 30; r =20.42, p = 0.02). Figure 1D: The diastolic blood pressure profiles of patients before, during and up to 120 minutes after 30 minute
administration of the highest dose of L-arginine (12 g; n = 10). Shaded area indicates time of L-arginine infusion. Dots and bars indicate mean6SEM.
doi:10.1371/journal.pone.0002347.g001
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infusion and 7 hours after starting intravenous quinine. No
significant changes in blood glucose were seen in patients who
received the larger doses of 6 g and 12 g. There were no
significant changes at any dose in creatinine, creatine kinase and
liver enzyme concentrations within 24 hours (data not shown).
Table 2 shows the maximum changes in the biochemical
paramenters up to 2 hours after the start of infusion compared
to pre-infusion values in each dosing group. The time course of the
mean changes in venous blood potassium, bicarbonate, pH,
chloride, phosphate and glucose concentrations before and up to
120 mins after administration of the maximum dose of 12 g are
shown in Figures 2B, 3B, 4B, 5B, 7B and 8B.
Discussion
We have previously reported that in adults with moderately
severe malaria, L-arginine infusion is able to improve NO
bioavailability and endothelial function [5], suggesting the
potential for a similar beneficial effect if used as adjunctive
therapy in severe malaria. We now show that relatively rapid
infusion of a single L-arginine infusion was safe at doses of up to
12 g infused at a rate of 24 g/hour in adults with moderately
severe malaria.
Our findings are in agreement with other studies showing
transient, modest, clinically insignificant decreases in blood
pressure using doses equal or higher to those used in our study
[14,22]. The fall in blood pressure with L-arginine infusion is
thought to be related to an increase in vascular NO synthesis [22].
In adult patients with sepsis, bolus arginine infusion at doses of
0.2g/kg causes a transient but significant decrease in mean arterial
pressure [23]. In contrast, slower rates of infusion (,1.1g/hr over
3 days) in adult sepsis cause no hemodynamic effects [24]. These
findings indicate that both the dose and rate of infusion of L-
arginine determine its hemodynamic effects. Despite minor effects
on blood pressure, the doses used in our study were still able to
significantly improve endothelial function [5].
Although not clinically significant, L-arginine infusion caused
modest, transient and, dose-dependent increases in chloride and
decreases in bicarbonate and pH. These changes were not
Figure 2. Effects of L-arginine hydrochloride infusion on whole
blood potassium concentrations. Figure 2A: Relationship be-
tween dose/weight (mg/kg) of infused L-arginine and the maximal
increase in whole blood potassium concentration at any time during or
in the two hours following infusion (n = 30; r = 0.73, p,0.001).
Figure 2B: Whole blood potassium concentrations of patients before
and after 30 minute administration of the highest dose of L-arginine
(12 g; n = 10). Shaded area indicates time of L-arginine infusion. Dots
and bars indicate mean6SEM.
doi:10.1371/journal.pone.0002347.g002
Figure 3. Effects of L-arginine hydrochloride infusion on
venous blood bicarbonate concentrations. Figure 3A: Relation-
ship between dose/weight (mg/kg) of infused L-arginine and the
maximal decrease in venous blood bicarbonate concentration at any
time during or in the two hours following infusion (n = 30; r =20.53,
p = 0.003). Figure 3B: Venous blood bicarbonate concentrations of
patients before and after 30 minute administration of the highest dose
of L-arginine (12 g; n = 10). Shaded area indicates time of L-arginine
infusion. Dots and bars indicate mean6SEM.
doi:10.1371/journal.pone.0002347.g003
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associated with changes in respiratory or pulse rate, or an increase
in lactate or the anion gap, and were likely due to the hydrogen
and chloride ion components of the L-arginine hydrochloride
infusion. Our results are consistent with an experimental study of
canine sepsis which showed that infusion of L-arginine hydro-
chloride resulted in a dose-dependent decrease in bicarbonate and
pH with an increase in chloride but not in lactate or anion gap
[25]. As the only commercially available intravenous formulation
of L-arginine registered for use in humans, L-arginine hydrochlo-
ride contains 4.75 mEq of hydrogen and chloride ions per gram.
In this pharmacokinetic, safety and proof-of-concept study, L-
arginine hydrochloride was given at a relatively rapid rate of
infusion. If given as adjunctive therapy in severe malaria, L-
arginine hydrochloride would likely be given less rapidly as a
prolonged infusion which is more likely to allow compensatory
mechanisms to ameliorate any effects of the hydrochloride on
acid-base status.
Renal impairment is common in adult severe malaria. In
considering the risk of acidosis in patients with renal failure, it is
noteworthy that rapid infusion of higher doses of L-arginine
hydrochloride (30 g over 30 mins) in patients with end stage renal
failure resulted in no change in arterial pH [26]. In healthy
subjects, L-arginine infusion improves renal blood flow and
glomerular filtration rate [27,28]. We found no evidence for an
adverse effect of L-arginine on renal function in patients with
moderately severe malaria, who by definition had normal renal
function. Intravenous L-arginine has also been shown to have no
deleterious effects on renal blood flow or glomerular filtration rate
in patients with renal impairment [28].
As with other cationic amino acids, intracellular uptake of L-
arginine results in displacement of intracellular potassium into the
extracellular fluid [15]. Increases in plasma potassium following L-
arginine infusion are well-described [29]. Mean increases in
plasma potassium of 1.2360.17 mmol/L (33%) have been
described in eight normal adults following high dose (30 g;
,0.5 g/kg) infusion over 30 minutes [16]. The risk of clinically
significant hyperkalemia with this relatively rapid high dose
infusion is higher in patients with underlying renal failure,
particularly those with baseline hyperkalemia and/or concurrent
spironolactone therapy [26]. The increase in potassium in patients
with moderately severe malaria who received up to 12 g was
transient and clinically insignificant. In a subgroup of African
children with both severe malaria and acidosis, hyperkalemia
Figure 4. Effects of L-arginine hydrochloride infusion on
venous blood pH. Figure 4A: Relationship between dose/weight
(mg/kg) of infused L-arginine and the maximal decrease in venous
blood pH at any time during or in the two hours following infusion
(n = 30; r =20.48, p = 0.007). Figure 4B: Venous blood pH in patients
before and after 30 minute administration of the highest dose of L-
arginine (12 g; n = 10). Shaded area indicates time of L-arginine infusion.
Dots and bars indicate mean6SEM.
doi:10.1371/journal.pone.0002347.g004
Figure 5. Effects of L-arginine hydrochloride infusion on
venous blood chloride concentrations. Figure 5A: Relationship
between dose/weight (mg/kg) of infused L-arginine and the maximal
decrease in venous blood chloride at any time during or in the two
hours following infusion (n = 30, r = 0.6, p,0.001). Figure 5B: Venous
blood chloride in patients before and after 30 minute administration of
the highest dose of L-arginine (12 g; n = 10). Shaded area indicates time
of L-arginine infusion. Dots and bars indicate mean6SEM
doi:10.1371/journal.pone.0002347.g005
Safety of Arginine in Malaria
PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e2347
(K+.5.5 mmol/L) was found in 16%, and was associated with
increased mortality [30]. In adults, only 1 (2%) of a group of 51
consecutive patients with severe malaria defined by modified
WHO criteria had a potassium level .5.5 mmol/L on admission
[5]. However, future initial phase 2 studies in severe malaria will
necessitate exclusion of hyperkalemic subjects, slow infusion rates
and caution with patients with renal failure. Subclinical hypo-
phosphatemia has been described in falciparum malaria [31], and
clinically insignificant hypophosphatemia has been seen with rapid
infusion higher doses (0.5 g/kg) of L-arginine [16]. However, there
were no significant changes in plasma phosphate concentrations in
the doses used in this study.
Because L-arginine increases the secretion of insulin [17] review
articles have stated that L-arginine may cause hypoglycemia [14].
However there have been no published case reports or series to
suggest this, likely because L-arginine also increases glucagon
production [17]. To our knowledge, the only clinical trial
reporting significantly altered blood glucose following L-arginine
infusion described a significant increase in mean blood glucose
following a dose of 0.5 g/kg [32]. In our study, one patient who
received the lowest dose (3 g) experienced a decrease in blood
glucose but not to the hypoglycemic range. Decreases in blood
glucose were not seen in patients who received the larger doses of
6 g and 12 g. The patient was simultaneously receiving quinine
infusion, a drug well known to increase insulin secretion and
reduce blood glucose, even in non-severe malaria [33]. With the
replacement of quinine by artesunate as treatment of choice for
severe malaria, the risk of hypoglycemia in severe malaria has
been significantly reduced [1]. The lack of a dose-response of L-
arginine on glucose in our series, an alternative explanation for a
fall in one patient, the use of artesunate in severe malaria, and the
hyperglycemic effect of higher doses of L-arginine in other series
[32], all suggest that adjunctive L-arginine is unlikely to have
hypoglycemic effects in phase 2 studies in severe malaria.
Transient pain at the infusion site seen in 7% of patients in this
study has also been described in other settings and is likely related
to the hypertonicity of the L-arginine solution. Other rare adverse
effects reported as single case reports in the literature were not
seen in this study including extravasation reactions [34] and
anaphylaxis [35].
There are limited data on the safety and efficacy of adjunctive
L-arginine monotherapy in other severe infections in animals and
humans [23–25,36]. Studies of intravenous L-arginine infusion in
patients with sepsis [23,24] have reported hemodynamic but not
biochemical or clinical endpoints. Trials of enteral preparations
containing L-arginine in critically ill patients have shown
Figure 6. Effects of L-arginine hydrochloride infusion on
venous blood lactate concentrations and anion gap.
Figure 6A: Relationship between dose/weight (mg/kg) of L-arginine
and change in venous blood lactate before and 4 hours after infusion
(n = 30; ns). Figure 6B: Relationship between dose/weight (mg/kg) of
infused L-arginine and the maximal change in venous anion gap at any
time during or in the two hours following infusion (n = 30; ns).
doi:10.1371/journal.pone.0002347.g006
Table 2. Maximum changes in parameters at any time during and for 2 hours after L-arginine infusion (3–12g) compared to pre
infusion values (mean maximum change [range])
Dose 3g 6g 12g
SBP (mmHg) 23 (0 to 28) 26 (0 to 212) 29 (22 to 218)
DBP (mmHg) 24 (+2 to 210) 25 (22 to 28) 26 (22 to 210)
Potassium (mmol/L) 0.2 (20.1 to 0.2) 0.3 (0.1 to 0.4) 0.5 (0.2 to 0.7)
HCO3 (meq/L) 21 (1 to 23) 21.5 (1 to 23.5) 23 (21 to 26)
pH 20.005 (20.001 to 20.05) 20.01 (+0.05 to 20.05) 20.04 (20.02 to 20.06)
Chloride (mmol/L) 2 (0 to 3) 2 (21 to 3) 3 (2 to 5)
Lactate (mmol/L) 20.05 (1 to 22) 20.34 (0.05 to 22) 20.34 (1 to 22)
Anion Gap 0 (24 to 2) 21 (25 to 1) 22 (22 to 3)
Phosphate (mg/dL) 0.1 (20.1 to 0.2) 0.1 (20.2 to 0.2) 0.1 (20.1 to 0.2)
Glucose (mmol/L) 21.1 (23.1 to 0.3) 20.94 (23.1 to 0.47) 20.64 (21.3 to 1.3)
doi:10.1371/journal.pone.0002347.t002
Safety of Arginine in Malaria
PLoS ONE | www.plosone.org 7 June 2008 | Volume 3 | Issue 6 | e2347
conflicting results [37,38]. The uncertain contribution of other
components of enteral formulae limits the interpretation of the
effects of L-arginine. With clear differences in pathophysiology
[5,39–41], safety and efficacy findings in other infections are
difficult to extrapolate to severe malaria in humans although
studies are ongoing to address this.
A parallel efficacy study performed in the same patients
reported here [5], has shown that L-arginine increases NO
production and restores endothelial function in falciparum malaria
and may have the potential for a beneficial role as adjunctive
therapy in severe malaria. The safety data in this study
demonstrate that a single relatively rapid intravenous infusion of
up to 12 g has no clinically significant hemodynamic, biochemical
or local adverse effects in patients hospitalized with moderately
severe malaria. Trials of L-arginine as adjunctive therapy can be
extended to phase 2 studies in adults with severe malaria, where
careful assessment of safety will also be required.
Supporting Information
Protocol S1 Trial Protocol.
Found at: doi:10.1371/journal.pone.0002347.s001 (0.53 MB
DOC)
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Figure 7. Effects of L-arginine hydrochloride infusion on
plasma phosphate concentrations. Figure 7A: Relationship
between dose/weight (mg/kg) of infused L-arginine and the maximal
decrease in plasma phosphate concentration at any time during or in
the two hours following infusion (n = 30; r =20.06, p = 0.8). Figure 7B:
Plasma phosphate concentrations of patients before and after
30 minute administration of the highest dose of L-arginine (12 g;
n = 10).. Shaded area indicates time of L-arginine infusion. Dots and bars
indicate mean6SEM.
doi:10.1371/journal.pone.0002347.g007
Figure 8. Effects of L-arginine hydrochloride infusion on blood
glucose concentrations. Figure 8A: Relationship between dose/
weight (mg/kg) of infused L-arginine and the maximal decrease in
whole blood glucose concentration at any time during or in the two
hours following infusion (n = 30; r =20.27, p = 0.14). Figure 8B: Whole
blood glucose concentrations of patients before and after 30 minute
administration of the highest dose of L-arginine (12 g; n = 10). Shaded
area indicates time of L-arginine infusion. Dots and bars indicate
mean6SEM.
doi:10.1371/journal.pone.0002347.g008
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